Benzamide-d5

Benzamide-d5 (Benzenecarboxamide-d5) is deuterium labeled Benzamide. Benzamide (Benzenecarboxamide) is a potent poly (ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH) -induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature[1].

Product Specifications

CAS Number

[1235489-47-0]

Product Name Alternative

Benzenecarboxamide-d5; Phenylamide-d5

UNSPSC

12352005

Target

Endogenous Metabolite; Isotope-Labeled Compounds; PARP

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease; Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Others

Smiles

O=C(N)C1=C([2H])C([2H])=C([2H])C([2H])=C1[2H]

Molecular Formula

C7H2D5NO

Molecular Weight

126.17

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Cosi C, et al. Benzamide, an inhibitor of poly (ADP-ribose) polymerase, attenuates methamphetamine-induced dopamine neurotoxicity in the C57B1/6N mouse. Brain Res. 1996 Oct 7;735 (2) :343-8.